It was able to predict the efficacy of some established combination therapies for NSCLC, such as BRAF/MEK and EGFR/mTOR inhibitors, but also identified brand new recipes. For example, it suggested ...
These are the receptor tyrosine kinases (for example, EGFR, ERBB2, platelet-derived growth ... PIK3CA, Akt and mTOR). These three groups of targets are mechanistically linked because most receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback